Based on Chinese clinical practice guideline on the management of ulcerative colitis (2023, Xi’an) : interpretation of the highlights of 2024 AGA guideline on pharmacological management of moderate-to-severe ulcerative colitis
10.3760/cma.j.cn101480-20250604-00084
- VernacularTitle:基于《中国溃疡性结肠炎诊治指南（2023年·西安）》：解析2024美国胃肠病协会中重度溃疡性结肠炎药物管理更新亮点
- Author:
Kaichun WU
1
Author Information
1. 空军军医大学西京医院消化内科，西安 710032
- Publication Type:Journal Article
- Keywords:
Ulcerative colitis;
Biological agents;
Janus kinase inhibitors;
Sphingosine-1- phosphate receptor modulators
- From:
Chinese Journal of Inflammatory Bowel Diseases
2025;09(4):265-273
- CountryChina
- Language:Chinese
-
Abstract:
With the in-depth exploration of the nature of ulcerative colitis (UC) and the continuous advancement of new drug research and development, coupled with the continuous emergence of a large number of new evidence-based medicine evidence, the treatment concept of ulcerative colitis is undergoing rapid iterative updates. In 2024, the American Gastroenterological Association (AGA) released the "AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis", innovatively proposing the "top-down" treatment concept that advanced therapeutic drugs such as biological agents, Janus kinase (JAK) inhibitors, and sphingosine-1-phosphate (S1P) receptor modulators can be used as first-line treatment options for moderate to severe UC, and constructing a stratified treatment decision-making system based on previous treatment responses. This article, in comparison with the "Chinese Guidelines for the Diagnosis and Treatment of Ulcerative Colitis (2023·Xi'an) ", systematically combs the new concepts and new drugs contained in the AGA guidelines, and deeply explores its important guiding value for the optimization of clinical practice of moderate to severe UC in China. The aim is to help clinicians have a more comprehensive understanding of the cutting-edge strategies for UC treatment at home and abroad, improve the level of UC diagnosis and treatment, and thus bring greater benefits to patients.
